Research programme: selective interleukin-2 receptor agonist - Anaveon
Alternative Names: Humanized NARA 1 antibody - AnaveonLatest Information Update: 28 Mar 2023
At a glance
- Originator Anaveon
- Class Adjuvants; Antibodies; Antineoplastics; Immunotherapies; Interleukins
- Mechanism of Action Immunostimulants; Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer